▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #123 by analyst upside · 2026-09-28
NMRA
Neumora Therapeutics, Inc.
Healthcare · Market Cap $127M · P/E 0x
ANALYST PRICE TARGET
+806.6%
implied upside to consensus target
Current Price $0.68
Consensus Target $6.14
Bull Target $14.0
Bear Target $3.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
0
52-Week Low $0.63
52-Week High $3.65
YTD Return -59.2%
FUNDAMENTALS
Market Cap $127M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.23
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.63
52-Week High $3.65
Current Price $0.68
Bear Target $3.0
Bull Target $14.0
● Now $0.68 ● Target $6.14
TRADING DATA
Avg Volume 1.0M
YTD Return -59.2%
Analyst Count 7
Consensus Buy
Upside to Target +806.6%
Last Updated 2026-09-28

ANALYST SUMMARY

Neumora Therapeutics, Inc. (NMRA) is currently trading at $0.68 with a Wall Street consensus price target of $6.14, implying potential upside of 806.6% over the next 12 months. 7 analysts currently cover NMRA, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $3.0.

NMRA operates in the Healthcare sector with a market capitalisation of $127M. The stock is down 59.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.63 – $3.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NMRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Outperform → Outperform 2026-07-13 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-06-18 Building track record
Needham - Reiterated
Buy → Buy 2026-06-16 20% win rate (5 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-16 31% win rate (48 calls)
Guggenheim reit
Buy → Buy 2026-03-31 62% win rate (8 calls)
Needham reit
Buy → Buy 2026-03-31 20% win rate (5 calls)
William Blair ↑ Upgrade
Market Perform → Outperform 2026-02-17 44% win rate (9 calls)
Leerink Partners ● Initiated
Outperform 2026-01-12 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →